ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations

Rhea-AI Filing Summary

ALX Oncology Holdings SVP Shelly Wong reported an open-market sale of 1,404 shares of Common Stock at a weighted average price of $2.04 per share. According to the filing, the shares were sold to satisfy her tax obligations related to vesting of restricted stock units.

After this transaction, she directly holds 88,401 shares, which includes 3,000 shares acquired under the company’s employee stock purchase plan on June 30, 2026.

Insider Trade Summary

Net Seller: 1,404 shares

Net Sell 1 txn

Insider Wong Shelly

Role SVP, FINANCE AND CAO

Sold 1,404 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,404	$2.04	$3K

Holdings After Transaction: Common Stock — 88,401 shares (Direct)

Footnotes (3)

1. F1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.

Key Figures

Shares sold: 1,404 shares Weighted average sale price: $2.04 per share Share price range: $2.02–$2.04 per share +2 more

5 metrics

Shares sold 1,404 shares Open-market sale on July 1, 2026

Weighted average sale price $2.04 per share Common Stock sale

Share price range $2.02–$2.04 per share Multiple sale transactions

Shares held after transaction 88,401 shares Direct ownership following sale

ESPP shares included 3,000 shares Acquired June 30, 2026 under employee stock purchase plan

Key Terms

restricted stock units, weighted average price, employee stock purchase plan

3 terms

restricted stock units financial

"tax obligations in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

employee stock purchase plan financial

"Includes 3,000 shares acquired under the Issuer's employee stock purchase plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 04:31 PM Accepted by SEC EDGAR 07/06/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What insider transaction did ALXO executive Shelly Wong report?

Shelly Wong reported selling 1,404 ALXO Common Stock shares in an open-market transaction. The weighted average sale price was $2.04 per share, and the filing states the sale was made specifically to cover tax obligations from restricted stock unit vesting.

Why did Shelly Wong sell ALXO shares in this Form 4 filing?

The filing explains that Shelly Wong sold the shares to satisfy tax obligations arising from vesting restricted stock units. This indicates the sale was a tax-related event rather than a discretionary portfolio move, which typically carries weaker signaling value for investors.

How many ALXO shares does Shelly Wong hold after this transaction?

Following the reported sale, Shelly Wong directly holds 88,401 shares of ALX Oncology Common Stock. This total includes 3,000 shares acquired through the company’s employee stock purchase plan on June 30, 2026, as disclosed in the filing’s footnotes.

What price range were Shelly Wong’s ALXO shares sold at?

The filing reports a weighted average sale price of $2.04 per ALXO share. Footnotes clarify that the shares were sold in multiple transactions, with individual prices ranging between $2.02 and $2.04 per share, and detailed breakdowns are available upon request.

Is Shelly Wong’s ALXO share sale part of routine compensation events?

The sale is tied to tax obligations from vesting restricted stock units, suggesting a routine compensation-related event. Such transactions are generally driven by tax requirements rather than views on the stock’s prospects, based on the description provided in the filing’s footnotes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wong Shelly

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE AND CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		1,404	D	$2.04(2)	88,401(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.

	/s/ Shelly Wong	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)